Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Fate Therapeutics (NQ: FATE )

2.290 +0.220 (+10.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics

< Previous 1 2 3 4 5 6 7 8 9 Next >
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Expert Ratings for Fate Therapeutics
Via Benzinga
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
FATE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FATE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A GLOBAL AND LEADING FIRM, Encourages Fate Therapeutics, Inc. Investors with Loses to Secure Counsel Before Important Deadline in Securities Class Action - FATE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IBM, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A RANKED AND LEADING FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FATE
From Pomerantz LLP
Via GlobeNewswire
Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Don’t forget to check out our premarket coverage here Fate Therapeutics, Inc. (NASDAQ: FATE) fell 4.1% to $6.13 in pre-market trading. Fate Therapeutics is expected to report Q4 results on Tuesday,... 
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results
From Fate Therapeutics, Inc.
Via GlobeNewswire
Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
ROSEN, A RESPECTED AND LEADING FIRM, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FATE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, IBM, and FATE and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FATE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, IBM, and FATE and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Fate Therapeutics, Inc. (FATE) Shareholder Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Fate Therapeutics, Inc.
From Robbins LLP
Via Business Wire
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Fate Therapeutics, Inc. (FATE) Investors and Encourages Investors to Contact the Firm Before March 22, 2023
From Kirby McInerney LLP
Via Business Wire
ROSEN, A TOP RANKED LAW FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Fate Therapeutics, Inc. (NASDAQ: FATE) Investor Notice: Lawsuit Alleges Securities Laws Violations
San Diego, CA -- (SBWIRE) -- 01/31/2023 -- An investor, who purchased NASDAQ: FATE shares, filed a lawsuit against Fate Therapeutics, Inc over alleged violations of Federal Securities Laws. 
Via SBWire
NOTICE: Investors in Fate Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – FATE
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FATE, and Sotera and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
5 Cheapest Health Care Stocks You Should Think About
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
ROSEN, LEADING INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
From Glancy Prongay & Murray LLP
Via Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
From Law Offices of Howard G. Smith
Via Business Wire
INVESTOR NOTICE: Fate Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Fate Therapeutics Class Action Lawsuit – FATE
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate. 
Via MarketBeat
Topics Workforce
Exposures Layoff Product Safety
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.